No­var­tis' Tafin­lar/Mekin­ist com­bo for melanoma gets pri­or­i­ty re­view des­ig­na­tion; Fo­s­un Phar­ma backs joint ven­ture's $190M share is­sue

→ Last Oc­to­ber No­var­tis $NVS won a break­through des­ig­na­tion for a com­bi­na­tion of Tafin­lar and Mekin­ist for its work in­volv­ing pa­tients with stage III melanoma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER